

## Response

I am writing to respond to your request sent on the 28<sup>th</sup> November 2016. OUH can confirm that it holds the data that you requested.

Drug Name	Long Description1 (group)	Dermatology	Gastroenterology	Rheumatology
ABATACEPT	Abatacept (Orencia)			38
Adalimumab	Adalimumab (Humira)	34	313	314
ETANERCEPT	Etanercept (Enbrel)	8		199
	Etanercept biosimilar (Benepali)	<5		98
GOLIMUMAB	Golimumab (Simponi)			79
INFLIXIMAB	Infliximab (Remicade)		21	19
	Infliximab biosimilar (Inflectra)	<5	60	<5
	Infliximab biosimilar (Remsima)	14	255	20
RITUXIMAB	Rituximab (MabThera)	<5	<5	119
SECUKINUMAB	Secukinumab (Cosentyx)	19		
TOCILIZUMAB	Tocilizumab (RoActemra)		0	0
USTEKINUMAB	Ustekinumab (Stelara)	35	<5	11
VEDOLIZUMAB	Vedolizumab (Entyvio)		125	

## Request

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below.

	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)			
Adalimumab (Humira)			
Apremilast (Otezla)			
Certolizumab Pegol (Cimzia)			
Etanercept (Enbrel)			
Etanercept biosimilar (Benepali)			
Golimumab (Simponi)			
Infliximab (Remicade)			
Infliximab biosimilar (Inflectra)			
Infliximab biosimilar (Remsima)			
Rituximab (MabThera)			
Secukinumab (Cosentyx)			
Ixekizumab (Taltz)			
Tocilizumab (RoActemra)			
Ustekinumab (Stelara)			
Vedolizumab (Entyvio)			